CNR1 and Parkinson disease: For example, activation of TRPV1 channels, whose activation can both exacerbate and counteract some of the major symptoms in animal models of Parkinson’s and Huntington’s diseases, is the best-established non-CB1, non-CB2-receptor-mediating action of AEA [101–105].